Retension Pharmaceuticals Inc(RTSN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
RTSN
New Retension Pharmaceuticals Inc
$15.50
+0.50 ▲ +3.33%
Oct 23 at 5:29 AM ET (Korea 10/23 18:29)$16.39
+0.89 ▲ +5.74%
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 23.62% | Shs Outstand | 7.9M | Perf Week | 26.95% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 6.4M | Perf Month | - |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | - | Inst Own | 22.03% | Short Float | - | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | - | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | - | Perf YTD | 55% |
| Book/sh | -1.89 | P/C | 9.57 | EPS past 3/5Y | - | ROE | - | 52W High | -16.85% ($18.64) | Perf Year | - |
| Cash/sh | 1.62 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 60.46% ($9.66) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 22.28% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 2.28 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.61 | EPS Q/Q | - | Profit Margin | - | RSI (14) | - | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.61 | Sales Q/Q | - | SMA20 | 15.32% ($13.44) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 15.32% ($13.44) | Rel Volume | 0.55 | Prev Close | $15 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 15.32% ($13.44) | Avg Volume(3M) | 0.22M | Price | $15.5 |
| IPO | 2026/10/9 | Option/Short | No/Yes | Trades | 1199 | Volume | 121,683 | Change | 3.33% |
Company
💊 조절되지 않는 고혈압과 치료 저항성 고혈압을 겨냥한 임상 단계 바이오테크 기업입니다. 2023년 설립되어 미국에 본사를 두고 있으며, 하루 한 번 먹는 경구용 5형 포스포디에스테라아제(PDE-5) 억제제 단일 후보물질을 임상 2상 후기 시험에서 개발하고 있습니다.
Quote
Over the past 1 year, roughly in the middle
17% below its 1-year high.
Now $15.50
52w low$9.6652w high$18.64
52W Range65%
Volume 121,683
Traded less than usual. That is 55% of its average volume.
B
Overall · fairly good
We judged 3 of the 8 questions below. 1 rate excellent.
No data for growth, valuation, earnings, outlook, dividends, or not applicable.
Has it trended upward long-term? B
Long-term returns are roughly flat
Tap to view numbers
How about dividends?
No dividend
There is no profit to distribute yet.
Who owns it? B
Ownership is about average
Institutions hold 22.0%.
Tap to view numbers
Peer comparison Biotechnology
It ranks #336 of 594 in the industry
Based on market cap of $129M.
MENS#335 Jyong Biotech Ltd $129M PER - RTSN#336 Retension Pharmaceuticals Inc $129M PER - 
TLSA#337 Tiziana Life Sciences Ltd $128M PER - 
ARMP#338 Armata Pharmaceuticals Inc $128M PER - 
HURA#339 TuHURA Biosciences Inc $128M PER - Reads on this stock 1 posts
FAQ
FAQ
What kind of company is RTSN?
RTSN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RTSN?
The market cap of RTSN is approximately $129M, ranking 4,330 within its sector.
What is the 52-week high and low for RTSN?
RTSN has recorded a 52-week high of $18.64 and a low of $9.66.
Briefs · earnings · signals, first Telegram · KakaoTalk channels
